The financing secures funds to advance the clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
CDSCO to fast-track trials and approval for COVID19 vaccine
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
Subscribe To Our Newsletter & Stay Updated
